PHAT Investors Have Opportunity to Join Phathom Pharmaceuticals, Inc. Fraud Investigation with SBS Law

Schall, Brown & Schwartz LLP, a shareholder rights firm, is investigating claims on behalf of Phathom Pharmaceuticals (NASDAQ: PHAT) investors for alleged securities-law violations. The investigation stems from Phathom's July 30, 2026 cut to its full-year revenue forecast after the company had reaffirmed guidance as recently as April; shares fell sharply on the news.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.